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ABSTRACT We recently reported the positional cloning
of a candidate gene for hereditary hemochromatosis called
HFE. The gene product, a member of the major histocompat-
ibility complex class I-like family, was found to have a
mutation, Cys-282 3 Tyr (C282Y), in 85% of patient chro-
mosomes. This mutation eliminates the ability of HFE to
associate with b2-microglobulin (b2m) and prevents cell-
surface expression. A second mutation that has no effect on
b2m association, H63D, was found in eight out of nine patients
heterozygous for the C282Y mutant. In this report, we dem-
onstrate in cultured 293 cells overexpressing wild-type or
mutant HFE proteins that both the wild-type and H63D HFE
proteins form stable complexes with the transferrin receptor
(TfR). The C282Y mutation nearly completely prevents the
association of the mutant HFE protein with the TfR. Studies
on cell-associated transferrin at 37°C suggest that the over-
expressed wild-type HFE protein decreases the affinity of the
TfR for transferrin. The overexpressed H63D protein does not
have this effect, providing the first direct evidence for a
functional consequence of the H63D mutation. Addition of
soluble wild-type HFEyb2m heterodimers to cultured cells
also decreased the apparent affinity of the TfR for its ligand
under steady-state conditions, both in 293 cells and in HeLa
cells. Furthermore, at 4°C, the added soluble complex of
HFEyb2m inhibited binding of transferrin to HeLa cell TfR in
a concentration-dependent manner. Scatchard plots of these
data indicate that the added heterodimer substantially re-
duced the affinity of TfR for transferrin. These results estab-
lish a molecular link between HFE and a key protein involved
in iron transport, the TfR, and raise the possibility that
alterations in this regulatory mechanism may play a role in
the pathogenesis of hereditary hemochromatosis.
Hereditary hemochromatosis (HH) is an autosomal recessive
disorder of iron metabolism and represents one of the most
common inherited disorders in individuals of Northern Euro-
pean descent with an estimated carrier frequency between 1 in
8 and 1 in 10 (1–3). In patients with HH, excessive iron
deposition in a variety of organs leads to multiorgan dysfunc-
tion (4, 5). Recently, we reported a mutation in a major
histocompatibility complex (MHC) class I-like gene, initially
called HLA-H (6) and now renamed HFE. Eighty-three
percent of HH patient DNAs were found to be homozygous for
this mutation, which consists of a single base transition of G to
A and results in a change of Cys-282 3 Tyr (C282Y).
Subsequent reports have confirmed the high frequency of this
founder mutation in other HH patients (7–9).
The HFE protein is similar to MHC class I family molecules.
All four of the invariant cysteine residues that form disulfide
bridges in the a2 and a3 domains of MHC class I protein are
present in HFE. One of these conserved cysteine residues is
altered by the C282Y mutation. Coimmunoprecipitation stud-
ies of cell lysates from human embryonic kidney cells trans-
fected with wild-type or mutant HFE cDNA, demonstrate that
wild-type HFE binds b2-microglobulin and that the C282Y
mutation, completely abrogates this interaction (10, 11). Im-
munofluorescence and subcellular fractionations demon-
strated that wild-type HFE is localized mainly on the cell
surface whereas, the C282Y mutant protein is primarily intra-
cellular (10, 11).
A second missense mutation, His-63 3 Asp (H63D) has
been reported to be enriched in hemochromatosis patients who
are heterozygous for the C282Y mutation (6, 9). The func-
tional consequence of this mutation has remained unclear.
Recent studies demonstrated that the H63D mutation does not
alter either the interaction with b2-microglobulin or the sur-
face expression of the protein (10). By analogy to MHC class
I structure, this mutation is located on the loop between the
third and fourth b strands of the peptide-binding domain (12)
and has been hypothesized to alter the manner in which HFE
interacts with associating proteins or ligands (6).
The precise mechanism by which a MHC class I-like protein
can influence iron homeostasis has remained obscure. To
investigate this we utilized cell-surface labeling to detect
potential HFE interacting proteins. We show that the HFE
protein normally forms a stable complex with the transferrin
receptor (TfR), the molecule responsible for receptor-
mediated endocytosis of iron-bound transferrin (13–15). The
consequence of this interaction is that the receptor exhibits a
lower affinity for transferrin. The C282Y mutant protein forms
only a trace amount of this complex, allowing high affinity
transferrin binding to the uncomplexed TfR. By contrast,
steady-state measurements suggested that the H63D mutant
protein that does associate with the TfR has little influence on
the apparent affinity of the TfR for transferrin. Taken to-
gether, these results provide a molecular link between HFE
and iron metabolism and suggest how the major mutations may
contribute to HH.
MATERIALS AND METHODS
Cell Surface Protein Biotinylations. Construction of cell
lines overexpressing wild-type and mutant forms of the FLAG
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epitope-tagged HFE protein have been previously described
(10). Briefly, various HFE constructs cloned in pCDNA3.1
(Invitrogen) were introduced in 293 cells with Lipo-
fectAMINE (GIBCO) and clones isolated by selecting with
800 mgyml of G418 (GIBCO). For surface biotinylations, cells
(4 3 106) were seeded into 100-mm dishes and grown overnight
to 80% confluency. The plates were moved to 4°C and gently
washed four times with PBS. Sulfo-N-hydroxysuccinimide-LC
biotin (Pierce) was added in PBS to a final concentration of 500
mgyml and incubated on ice for 30 min. The biotin reagent was
removed and the plates washed four times with PBS containing
50 mM glycine. Cells were lysed in 500 ml of 25 mM TriszHCl,
pH 7.5, 150 mM NaCl plus 0.5% Nonidet P-40. Protein
concentrations were determined by BCA assay (Pierce) and 1
mg of protein was precleared with 25 mg of Protein-G-
Sepharose (Pharmacia) and immunoprecipated with either 10
mg of anti-HFE rabbit polyclonal antibody (CT1) (10), 50 mg
of FLAG (M2) mAb (Kodak), 5 mg of TfR monoclonal
antibody (Caltag, South San Francisco, CA) or 10 mg of
HLA-ABC antibody (Immunotech, Westbrook, ME). Precip-
itated proteins were separated on 4–20% Triszglycine poly-
acrylamide gels (Novex, San Diego), electroblotted to polyvi-
nylidene difluoride membranes (Novex) and biotinylated pro-
teins were visualized with 2 mgyml of streptavidin-horseradish
peroxidase (Pierce) followed by enhanced chemiluminescence
detection reagents (Amersham).
Immunoprecipitations and Western Blot Analysis. Cells
were lysed in the same buffer as above and precipitations
carried out with the same antibodies and concentrations except
that no preclearing step was carried out. Precipitated proteins
were separated and electroblotted to polyvinylidene difluoride
membranes as previously described (10). Gels were calibrated
using prestained molecular weight standards (Novex).
Measurements of Cell-Associated Transferrin at Steady-
State. Measurements of cell-associated transferrin were car-
ried out essentially as described (16) with the following
modifications. Cells were seeded at a density of 6 3 105 per
well in 6-well dishes coated with 0.01% fibronectin (Sigma)
and grown overnight. Cells were washed once with 2 ml of
DMEM-H21 (GIBCO) media supplemented with 1% fetal
bovine serum and then incubated at either 37°C or on ice with
varying concentrations of transferrin that include [125I]-diferric
transferrin (1 mCiymg; 1 Ci 5 37 GBq) (NEN) as a tracer (1⁄30
of the final concentration) in a final volume of 750 ml. To
determine the amount of nonspecific transferrin binding, cells
were simultaneously incubated under the same conditions but
in the presence of 1003 the molar concentration of cold
holo-transferrin (Sigma). After 20 min (37°C), the media was
removed and counted in a Beckman 9600 scintillation counter.
The cells were placed on ice and washed two times with media
containing 1% fetal bovine serum, and then lysed with 1% SDS
and counted. Specific cell-associated transferrin was calculated
by subtracting the nonspecific cell-associated transferrin from
the total. A second method was also used that utilized a
constant amount of labeled transferrin (5 nM) and increasing
amount of unlabeled transferrin to increase the total trans-
ferrin concentration. Identical results to those produced by the
first method were obtained. Transferrin binding in HeLa cells
at 4°C was measured exactly as cell-associated transferrin
except that the incubations were carried out at 4°C instead of
37°C and for 90 min instead of 20 min.
HeLa cells were grown to 80–90% confluence at 37°C at 5%
CO2. The cells were washed twice with PBS and detached from
the plates using 4 mM EDTAyPBS. The cells were counted and
diluted to 5 3 106 cells per ml in DMEM 1% fetal bovine
serum (Gibco) and 5 3 105 suspended cells were used for the
TfR binding assay. Binding assays were all done in duplicate.
Nonspecific binding was determined as for 293 cells. Soluble
HFE was added to the cells for 10 min at room temperature
prior to the addition of labeled transferrin where indicated.
Labeled transferrin (NEN) was added to the cells at concen-
trations ranging from 0.5–15 nM. The reaction volume was 500
mL. Incubations were carried out for 20 min, for experiments
performed at 37°C, or 90 min on ice for experiments per-
formed at 4°C. At the end of the incubation the cells were
pelleted at 3,000 rpm for 2 min. The supernatant was decanted
and radioactivity counted. The cells were gently washed four
times by resuspending the cells with 1 ml ice-cold DMEM 1%
fetal bovine serum and repelleting at low centrifugal force.
During the washing steps the cells were kept at 4°C. After the
final wash, the cells were resuspended in PBS and bound
radioactivity was counted. The amount of transferrin bound to
the cells was calculated by dividing the cpm bound to the cells
by the cpm counted in the supernatant, this ratio was converted
to a molar value by multiplying by the amount of transferrin
used in the experiment. The Kcell association and the apparent KD
were calculated from the negative slope of the line generated
by Scatchard analysis or by analyzing the binding curves
utilizing nonlinear regression; both methods yielded essentially
the same results.
Expression and Purification of Secreted HFE. Secreted
HFE was expressed in Chinese hamster ovary cells as follows:
A 59 XhoI site, a stop codon after the codon corresponding to
amino acid 298 (6) (residue 276 of the mature protein) and a
39 NotI site were inserted in the HFE gene by site-directed
mutagenesis. After verifying the sequence, the modified HFE
gene was subcloned into the expression vector PBJ5-GS that
carries the glutamine synthetase gene (Lonza Biologics, Berk-
shire, U.K.) as a selectable marker and as a means of gene
amplification in the presence of the drug methionine sulfoxi-
mine (17). The HFE expression plasmid was cotransfected
with a human b2m expression vector (18) into Chinese hamster
ovary K1 cells. Cell lines secreting HFEyb2m heterodimers
were identified by immunoprecipitation of supernatants of
[35S]-methionine metabolically labeled cells using an antibody
against human b2m (BBM.1) (19). A protein of molecular mass
of 43 kDa was coimmunoprecipitated with labeled b2m from
the supernatants, and was verified to be the truncated HFE
polypeptide chain by N-terminal sequencing of the purified
protein (yielding the sequences RLLRSHSLHYLF and IQRT-
PKIQVYSR corresponding to the correctly processed mature
forms of HFE and human b2m; data not shown). Soluble
HFEyb2m heterodimers were purified on a BBM.1 immuno-
affinity column, followed by separation of free b2m from the
heterodimers on a Superdex 75 HR 10y30 fast protein liquid
chromatography gel filtration column or by using an immu-
noaffinity column constructed with an HFE mAb raised
against the purified heterodimer (J.A.L. and P.J.B., unpub-
lished results).
RESULTS AND DISCUSSION
We initially utilized cell-surface labeling to detect potential
HFE interacting proteins. Human embryonic kidney cells (293
cells), engineered to overexpress either wild-type or mutant
forms of HFE, were treated with biotin-conjugated N-
hydroxysuccinimide to label proteins expressed on the cell-
surface. Subsequently, total cell lysates were immunoprecipi-
tated with previously characterized antibodies directed toward
the C-terminal peptide sequence of HFE or monoclonal
antibodies against the FLAG epitope tag that had been
engineered into the HFE protein (10). Biotinylated proteins
were detected with streptavidin-conjugated horseradish per-
oxidase. Lysates from parental 293 cells displayed little sur-
face-labeling in accordance with previous results demonstrat-
ing undetectable levels of HFE protein in these cells (Fig. 1 A
and B) (10). In contrast, prominent bands at 49 and 100 kDa
and the less intense bands at 12 and 200 kDa, were observed
in immunoprecipitates from lysates of cells overexpressing the
wild-type HFE; these bands were absent in immunoprecipi-
Biochemistry: Feder et al. Proc. Natl. Acad. Sci. USA 95 (1998) 1473
tates from cells overexpressing the C282Y mutant form of
HFE (Fig. 1 A and B). In previous studies it was demonstrated
that the plasma membrane-bound form of HFE was 49 kDa in
molecular mass and associated with b2m, a 12-kDa protein (10,
11). The presence of 49- and 12-kDa-labeled bands in HFE-
specific immune-complexes from wild-type HFE expressing
cells and their virtual absence in parental and C282Y mutant
expressing cells is consistent with their identity as HFE and
b2m. The fact that only trace amounts of the 100- and 200-kDa
proteins coimmunoprecipitated from lysates of the C282Y
mutant expressing cells suggests a specific interaction of these
proteins with the cell-surface form of HFE.
To further examine the specificity of the above protein
interactions with HFE, we performed immunoprecipitations
with antibodies that recognize the related HLA-A, B and C
proteins. These antibodies detected proteins at '45 kDa and
12 kDa, the predicted molecular masses of the HLA heavy
chain and b2m, but failed to coimmunoprecipitate the 100- and
200-kDa bands (Fig. 1D).
To identify the 100- and 200-kDa proteins that coimmuno-
precipitated with HFE, we investigated proteins known to
participate in iron homeostasis. Interestingly, the major carrier
of transferrin-bound iron, the TfR is known to display a
characteristic pattern of monomers and dimers migrating at
'100 and 200 kDa in denaturing gel electrophoresis (13–15).
To determine whether HFE could associate with the TfR, we
utilized TfR antibodies to immunoprecipitate surface-labeled
proteins from the three cell lines. A prominent protein of
molecular mass corresponding to the monomeric TfR and a
smaller amount of one corresponding to the dimeric form of
the TfR were seen in the parental 293 as well as the wild-type
HFE overexpressing cells. The C282Y mutant protein express-
ing cell line had less of both, (Fig. 1C). [However, studies of
cell-associated transferrin suggest that these cells had equiv-
alent numbers of receptors (see Fig. 3, compare A and B)]. Two
proteins with masses corresponding to those of HFE and b2m
(49 kDa and 12 kDa, respectively) were observed in immuno-
precipitates from the cells that overexpress wild-type HFE
protein. By contrast, little or no HFE protein was seen in
immunoprecipitates from parental 293 or C282Y mutant
protein expressing cells.
The HFEyTfR association results were corroborated by
performing coimmunoprecipitation experiments on unlabeled
total cell lysates. Immunoprecipitation with HFE antibodies
followed by blotting and probing with antibodies to TfR
demonstrated that the TfR was complexed with the wild-type
form of HFE. In contrast, very little TfR was observed in the
immunoprecipitates from the C282Y mutant cells (Fig. 2A).
Reprobing blots with the FLAG epitope antibodies to detect
HFE demonstrated that equivalent amounts of HFE were
being expressed and immunoprecipitated from each of the cell
lines except the parental 293 cells, as expected (Fig. 2B).
Performing the inverse experiment, wherein cell lysates were
first immunoprecipitated with TfR antibodies followed by
blotting with HFE antibodies, revealed that HFE coimmuno-
precipitated with the TfR from wild-type HFE expressing
cells; only a trace band was observed with C282Y and none
with the parental 293 cell line (Fig. 2C). The absence of HFE
in immunoprecipitates with TfR in parental 293 and near
absence in the C282Y mutant cell lines was not due to failure
to precipitate TfR; reprobing the blot with TfR antibodies
demonstrated that TfR protein was precipitated from each of
the cell lines, including C282Y (Fig. 2D). To further control for
the specificity of the HFE antibodies, we first immunoprecipi-
tated cell lysates with FLAG epitope antibodies to specifically
precipitate the HFEyFLAG fusion proteins followed by blot-
ting with TfR antibodies. As was observed in Fig. 2A, the TfR
was coimmunoprecipitated from cells expressing the FLAG-
tagged wild-type HFE protein, but not from cells expressing
the FLAG-tagged C282Y mutant HFE protein (Fig. 2E).
Experiments performed on an independent series of cell lines
engineered to express wild-type and mutant HFE that lacked
the FLAG epitope tag yielded identical results to those shown
in Fig. 2 when immunoprecipitations were carried out with
HFE and TfR antibodies (data not shown).
In immunoprecipitation experiments on unlabeled cell ly-
sates we included as a further control another mutant of HFE
wherein His-63 was replaced by aspartate (H63D). As with
wild-type HFE, the H63D protein is also expressed on the cell
surface and associates with b2m (10, 11). The association of
HFE with the TfR as assessed by coimmunoprecipitation
appeared unaffected by the H63D mutation (Fig. 2 A, C, and
E).
FIG. 1. Cell-surface labeling of HFE and association with TfR. (A)
HFE antibodies immunoprecipitate 12, 49, 100, and 200 kDa surface-
labeled proteins from wild-type HFE expressing cells. The coimmu-
noprecipitating proteins are greatly reduced or absent in immune
complexes from parental 293 or C282Y HFE mutant expressing cells.
(B) FLAG epitope antibodies also immunoprecipitate 12, 49, 100, and
200 kDa surface-labeled proteins in wild-type HFE expressing cells. As
in A, the coimmunoprecipitating proteins are greatly reduced or
absent in immune complexes from parental 293 or C282Y HFE mutant
expressing cells. (C) TfR antibodies immunoprecipitate 100- and
200-kDa surface-labeled proteins from parental 293, wild-type, and
C282Y HFE expressing cells and in addition, immunoprecipitate 12-
and 49-kDa proteins from wild-type HFE expressing cells. (D) HLA-
ABC antibodies fail to immunoprecipitate 100- and 200-kDa proteins
from parental 293 cells.
FIG. 2. Direct association of TfR with HFE. (A) HFE antibodies
coimmunoprecipitate TfR from wild-type and H63D HFE expressing
cells but very little from parental 293 or C282Y HFE mutant express-
ing cells. (B) HFE antibodies immunoprecipitate substantial amounts
of HFE protein from wild-type, C282Y and H63D HFE expressing
cells. (C) TfR antibodies coimmunoprecipitate HFE from wild-type
and H63D HFE expressor cells but not parental 293 and only a trace
from C282Y mutant expressing cells. (D) TfR antibodies immuno-
precipitate TfR protein from parental 293, and wild-type, C282Y and
H63D HFE expressing cells. (E) FLAG epitope (M2) antibodies
coimmunoprecipitate TfR from wild-type and H63D HFE expressing
cells but not parental 293 or C282Y HFE mutant expressing cells.
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To assess the biological effect of the HFEyTfR interaction,
we characterized the transferrin-binding properties of the TfR
in the presence or absence of HFE. For these studies we
examined the amount of [125I]-transferrin (diferric form) as-
sociated with intact 293 cells engineered to overexpress both
b2m and either wild-type HFE or one of two HFE mutant
forms, C282Y or H63D. The initial binding experiments were
performed at 37°C under which conditions the total cell-
associated [125I]-transferrin represents both surface-bound
and internalized ligand at steady-state (20, 21). The cell-
association of [125I]-transferrin saturated at 150–250 nM on
both C282Y mutant and wild-type HFE expressing cells (Fig.
3 A and B insets, which present data from two separate cell
clones for each the wild-type and mutant HFE). When sub-
jected to Scatchard analysis, the C282Y HFE mutant express-
ing clones showed a Kcell association for transferrin of '12 and 14
nM (Fig. 3A). A similar Kcell association for transferrin was found
in parental 293 cells (19 nM) (data not shown). By contrast, the
Kcell association for transferrin in the wild-type HFE expressing
clones, appeared to be increased 3- and 15-fold to Kcell association
values of 40 and 180 nM, respectively.
In contrast to the effect of wild-type HFE on Kcell association
for transferrin, the H63D mutation, while retaining the ability
to interact with the TfR (Figs. 1 and 2), did not appear to
increase the Kcell association for transferrin. Two clonal lines ex-
pressing the H63D mutant protein had apparent Kcell association for
transferrin of '12 and 20 nM (Fig. 3C). These values are nearly
identical to those obtained with the cell lines expressing the
C282Y mutant in which the HFE protein was absent from the cell
surface (Kcell association 5 12 and 14 nM). The total amount of
cell-associated transferrin in cell lines expressing the H63D
mutant (1. 8 3 10210 M) was 2 to 3-fold lower when compared
with the C282Y expressing cells (4–6 3 10210 M) (Fig. 3 A and
C). This may reflect clonal variation or may reflect an altered TfR
trafficking. Regardless, these data suggest that one functional
consequence of the H63D mutation appears to be the loss of the
ability of the HFE protein to increase the Kcell association for
transferrin. In lacking this property of the wild-type HFE protein,
HFE with the H63D mutation functionally resembles the C282Y
mutation.
As an alternative method to assess the effect of HFE on the
Kcell association for transferrin, we added a soluble form of
HFEyb2m heterodimers to the culture medium of parental 293
cells. The addition of the HFEyb2m heterodimers at 37°C
reduced cell-associated transferrin in a concentration-
dependent manner with maximal inhibition at 2 mM het-
erodimer (Fig. 3D). The apparent Ki for inhibition was 87 nM.
Similarly, in the presence of 2 mM soluble HFEyb2m het-
FIG. 3. Effect of HFE on cell-association of [125I]-transferrin. (A) Cell association of [125I]-transferrin in cells that overexpress the C282Y
(intracellular) mutant form of HFE. Approximately 9 3 105 cells (clone 10, h; and clone 12, n) were incubated with various concentrations of
transferrin at 37°C for 20 min (Inset). The data represent the mean of duplicate determinations corrected for nonspecific binding. Scatchard analysis
revealed an Kcell association of '12 and 14 nM, respectively. (B) Cell-association of [125I]-transferrin in cells overexpressing the wild-type (surface)
form of HFE (clone 7, E; clone 3, F). Scatchard analysis revealed that the Kcell association for transferrin was 180 and 40 nM, respectively. (C)
Cell-association of [125I]-transferrin in cells overexpressing the H63D mutant form of HFE (clone 3, ; clone 8, ). Scatchard analysis revealed
a Kcell association for transferrin to be 12 and 20 nM, respectively. (D) Inhibition of cell-associated [125I]-transferrin to the TfR on parental 293 cells
by addition of soluble HFEyb2m heterodimers. Parental 293 cells were preincubated with various amounts of soluble HFEyb2m heterodimers
followed by addition of 10 nM [125I]-transferrin. The amount of specific cell-associated transferrin was determined and plotted as a percent of that
observed in cells with no added HFE. The apparent Ki is 87 nM.
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erodimers the Kcell association for transferrin was increased 5-fold
to 100 nM (data not shown). Control experiments using an
identical amount of an MHC class I, H-2Kd (22) protein
complexed with human b2m failed to have any effect on the
cell-associated transferrin to 293 cells (data not shown).
To corroborate the inhibitory effects observed with soluble
HFEyb2m heterodimers on 293 cells we performed similar
studies on HeLa cells. Scatchard analysis of the cell-associated
transferrin data obtained for HeLa cells at 37°C revealed an
apparent Kcell association of 4.7 nM (Fig. 4A). In the presence of
either 150 nM or 1 mM soluble HFEyb2m heterodimers, the
apparent Kcell association increased to 11 nM or 50 nM, respec-
tively (Fig. 4A). An apparent Ki for inhibition of cell-associated
transferrin for the soluble HFEyb2m heterodimers was calcu-
lated to be 39 nM (Fig. 4B). To determine whether the increase
in the Kcell association for transferrin was specific for the HFE
protein, we added to the assay a classical MHC class I protein,
a purified soluble form of HLA-B27, complexed with b2m (23).
Addition of 100 nM HLA-B27 had no effect on the Kcell association
of transferrin binding to the TfR (Fig. 4A), demonstrating that
the inhibitory effect of the HFEyb2m heterodimers was spe-
cific to HFE, and was not attributable solely to the presence of
excess amounts of MHC class I molecules in the assay.
The transferrin binding studies were repeated at 4°C where
internalization of ligand is negligible, to determine whether the
observed effects of the soluble HFEyb2m heterodimers were
due to changes in the KD of the TfR for transferrin (24–26). We
utilized HeLa cells for these studies because of the high
nonspecific transferrin binding in 293 cells observed at 4°C.
Scatchard analysis of the binding data revealed that in the
absence of HFE, the TfR bound transferrin with an apparent
KD of 5 nM, which was similar to the Kcell association of 4.2 nM
observed at 37°C (Fig. 4C). In the presence of either 35nM or
1 mM soluble HFEyb2m heterodimers the apparent KD in-
FIG. 4. Soluble HFEyb2m heterodimers reduce the affinity of the TfR for transferrin. (A) Effect of HFEyb2m heterodimers on the
cell-association of [125I]-transferrin to HeLa cells at 37°C. Cell-associated [125I]-transferrin in HeLa cells in the presence of 0, 150, or 1,000 nM
HFE or 100 nM soluble HLA-B27yb2m heterodimers (Inset). Scatchard analysis of cell associated [125I]-transferrin in the presence of 0 nM (h),
150 nM (), or 1,000 nM HFE () revealed Kcell association values of 4.7 nM, 11 nM, and 50 nM, respectively and '1.0 3 106 transferrin binding
sites per cell. (Note: the addition of 1,000 nM soluble HFEyb2m heterodimers dramatically reduces cell-associated transferrin such that an accurate
x-intercept is difficult to obtain; the Kcell association 50 nM is estimated utilizing 1.0 3 106 binding sites per cell.) Addition of 100 nM soluble
HLA-B27yb2m heterodimers (n) to the assay had no effect. (B) Determination of the apparent Ki of soluble HFEyb2m heterodimers for
cell-associated transferrin inhibition in HeLa cells. Cells were preincubated at 37°C in various amounts of soluble HFEyb2m heterodimers and then
[125I]-transferrin was added to 5 nM. The amount of specific cell-associated transferrin was determined and plotted as a percent of that observed
in cells with no added HFE. The apparent Ki for HeLa is 39 nM. (C) Effect of HFEyb2m heterodimers on the binding of [125I]-transferrin to HeLa
cells at 4°C. Binding of [125I]-transferrin to HeLa cells in the absence or presence of 0, 35, or 1,000 nM HFE (inset). Scatchard analysis of
[125I]-transferrin binding in the presence of 0 (h), 35 (), or 1,000 nM () HFE revealed apparent KD values of 5 nM, 12 nM, and 75 nM, respectively
and '1.0 3 106 transferrin binding sites per cell. (Note: the addition of 1,000 nM soluble HFEyb2m heterodimers dramatically reduces transferrin
binding such that an accurate x intercept is difficult to obtain; the apparent KD of 75 nM is estimated utilizing 1.0 3 106 binding sites per cell.)
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creased to 12 and 75 nM, respectively, indicating that the
principal effect of added HFEyb2m heterodimers is to reduce
the affinity of the TfR for transferrin. Further, as was the case
for Kcell association at 37°C, addition of 100 nM soluble HLA-
B27yb2m heterodimers to the assay had no effect on trans-
ferrin binding at 4°C, supporting the specificity of the inhibi-
tion by HFE (data not shown). These experiments demon-
strate that wild-type HFE can lower the affinity of TfR for
transferrin.
The primary defects in hereditary hemochromatosis appear
to be both increased iron absorption in the small intestine and
increased iron deposition in major organs (4, 5). We have
demonstrated here that HFE forms a stable complex with the
TfR and decreases the affinity of transferrin binding. The
C282Y mutation largely eliminates this interaction. We have
also shown that the second missense mutation associated with
hemochromatosis, H63D, appears to have a similar functional
consequence in that it alters the ability of HFE to increase the
Kcell association for transferrin. The loss of HFE-repressor func-
tion for transferrin uptake could result in increased cellular
uptake of iron by some tissues, and contribute to iron depo-
sition in HH. How these mutations lead to increased iron
absorption in the intestine is unclear. Recent immunohisto-
chemical studies have localized HFE to the intracellular
portion of the cells in the deep crypts of the duodenum (27),
the same region where previous studies have localized the TfR
(28, 29). The role of the TfR in the cells of the deep crypts has
long been thought to be limited to servicing the proliferative
needs of these cells. In light of the association of HFE and the
TfR, one must now reconsider the role of transferrin and its
receptor in regulating intestinal iron absorption. Regardless of
the actual mechanism, the observations described here provide
a molecular link between HFE and iron metabolism and raise
the possibility that perturbation of the transferrinyTfR system
of iron transport is a previously unrecognized component of
HH disease. Furthermore, these results demonstrated that by
administering HFE protein in situ, the amount of transferrin
taken up by cells can be attenuated. Possibly the HFEyTfR
interaction provides a new target for therapeutic agents aimed
at influencing iron absorption and/or tissue distribution in iron
overload disorders.
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